FDA Approves Novartis’ Piqray Tablets for Breast Cancer

The FDA approved Novartis’ Piqray (alpelisib) as first PI3K inhibitor for breast cancer, to be used in combination with the FDA-approved endocrine therapy fulvestrant.

• The FDA also granted approval of the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit, to QIAGEN Manchester

Link to Statement: FDA approves first PI3K inhibitor for breast cancer

©2019 Bloomberg L.P. All rights reserved. Used with permission